Pfizer Gains European Rights to Specialist Biologic Product, Xiaflex
By Helen Scrutton
Pharma Deals Review: Vol 2008 Issue 103 (Table of Contents)
Published: 17 Dec-2008
DOI: 10.3833/pdr.v2008.i103.99 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Pfizer has gained European rights to Auxilium Pharmaceuticals’ Xiaflex™ (clostridial collagenase for injection) – a novel, first-in-class, late-stage biologic, for the treatment of Dupuytren's contracture and Peyronie's disease...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS